Evidence map›Paper›PMID 26565001›Full record

ArticleHaematologica2016

Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.

Bipin N Savani, Myriam Labopin, Didier Blaise, Dietger Niederwieser, Fabio Ciceri, Arnold Ganser, Renate Arnold, Boris Afanasyev, Stephane Vigouroux, Noel Milpied and 11 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Graft Source Choice.Advances in experimental medicine and biology · 2025
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide.Hematology. American Society of Hematology. Education Program · 2019
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 19 institutions in 10 countries.

Bipin N SavaniVanderbilt University Medical Center, Nashville, TN, USA Bipin.Savani@Vanderbilt.Edu.
Myriam LabopinEBMT Paris Study Office/CEREST-TC, Paris, France Department of Haematology, Saint Antoine Hospital, Paris, France INSERM UMR 938, Paris, France Université Pierre et Marie Curie, Paris, France.
Didier BlaiseDépartement d'Hématologie - Centre de Recherche en Cancérologie de Marseille - Aix-Marseille University, Institut Paoli Calmettes, Marseille, France.
Dietger NiederwieserUniversity Hospital Leipzig, Hematology, Oncology and Hemostaseology Divisions, Germany.
Fabio CiceriHematology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Arnold GanserHannover Medical School - Department of Haematology Hemostasis Oncology and Stem Cell Transplantation, Hannover, Germany.
Renate ArnoldCharité Universitätsmedizin Berlin, Campus Virchow Klinikum - Medizinische Klinik m. S. Hämatologie/Onkologie, Berlin, Germany.
Boris AfanasyevSaint Petersburg State Medical Pavlov University, Ratsa Gorbacheva Memorial Children's Institute, Hematology and Transplantology, St. Petersburg, Russia.
Stephane VigourouxCHU Bordeaux - Hôpital Haut-leveque, Pessac, France.
Noel MilpiedCHU Bordeaux - Hôpital Haut-leveque, Pessac, France.
Michael HallekUniversity of Cologne, Department of Medicine, Germany.
Jan J CornelissenErasmusMC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Rainer SchwerdtfegerDepartment of Haematology, Oncology Helios-Klinikum Berlin-Buch, Germany.
Emmanuelle PolgeEBMT Paris Study Office/CEREST-TC, Paris, France Department of Haematology, Saint Antoine Hospital, Paris, France INSERM UMR 938, Paris, France Université Pierre et Marie Curie, Paris, France.
Frédéric BaronDepartment of Medicine, Division of Hematology, University of Liège, Belgium.
Jordi EsteveDepartment of Hematology, Hospital Clinic, Barcelona, Spain.
Norbert C GorinDepartment of Hematology, Saint Antoine Hospital, APHP and University UPMS, Paris, France.
Christoph SchmidKlinikum Augsburg, Department of Hematology and Oncology, University of Munich, Augsburg, Germany.
Sebastian GiebelDepartment of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland.
Mohamad MohtyEBMT Paris Study Office/CEREST-TC, Paris, France Department of Haematology, Saint Antoine Hospital, Paris, France INSERM UMR 938, Paris, France Université Pierre et Marie Curie, Paris, France.
Arnon NaglerEBMT Paris Study Office/CEREST-TC, Paris, France Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Hôpital Cardiologique du Haut-Lévêque · FRHôpital Saint-Antoine · FRAix-Marseille Université · FRAssistance Publique – Hôpitaux de Paris · FRCharité - Universitätsmedizin Berlin · DEErasmus MC Cancer Institute · NLEuropean Society for Blood and Marrow Transplantation · FRFirst Pavlov State Medical University of St. Petersburg · RUHelios Hospital Berlin-Buch · DEHospital Clínic de Barcelona · ESMedizinische Hochschule Hannover · DESheba Medical Center · ILThe Maria Sklodowska-Curie National Research Institute of Oncology · PLUniversity Hospital Augsburg · DEUniversity Hospital Leipzig · DEUniversity of Cologne · DEUniversity of Liège · BEVanderbilt University Medical Center · USVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing numbers of patients are receiving reduced intensity conditioning regimen allogeneic hematopoietic stem cell transplantation. We hypothesized that the use of bone marrow graft might decrease the risk of graft-versus-host disease compared to peripheral blood after reduced intensity conditioning regimens without compromising graft-versus-leukemia effects. Patients who underwent reduced intensity conditioning regimen allogeneic hematopoietic stem cell transplantation from 2000 to 2012 for acute leukemia, and who were reported to the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation were included in the study. Eight hundred and thirty-seven patients receiving bone marrow grafts were compared with 9011 peripheral blood transplant recipients after reduced intensity conditioning regimen. Median follow up of surviving patients was 27 months. Cumulative incidence of engraftment (neutrophil ≥0.5×10(9)/L at day 60) was lower in bone marrow recipients: 88% versus 95% (P<0.0001). Grade II to IV acute graft-versus-host disease was lower in bone marrow recipients: 19% versus 24% for peripheral blood (P=0.005). In multivariate analysis, after adjusting for differences between both groups, overall survival [Hazard Ratio (HR) 0.90; P=0.05] and leukemia-free survival (HR 0.88; P=0.01) were higher in patients transplanted with peripheral blood compared to bone marrow grafts. Furthermore, peripheral blood graft was also associated with decreased risk of relapse (HR 0.78; P=0.0001). There was no significant difference in non-relapse mortality between recipients of bone marrow and peripheral blood grafts, and chronic graft-versus-host disease was significantly higher after peripheral blood grafts (HR 1.38; P<0.0001). Despite the limitation of a retrospective registry-based study, we found that peripheral blood grafts after reduced intensity conditioning regimens had better overall and leukemia-free survival than bone marrow grafts. However, there is an increase in chronic graft-versus-host disease after peripheral blood grafts. Long-term follow up is needed to clarify whether chronic graft-versus-host disease might increase the risk of late morbidity and mortality.

Indexed as

Bone Marrow TransplantationPeripheral Blood Stem Cell TransplantationRegistriesAdolescentAdultAgedAntineoplastic AgentsFemaleGraft vs Host DiseaseHumansLeukemia, Myeloid, AcuteMaleMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisRecurrenceAntineoplastic Agents

Identifiers

PMID26565001
PMCPMC4938329
OpenAlexW2273689910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.